Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.0 - $0.35 $0 - $1.39 Million
-3,967,720 Closed
0 $0
Q2 2022

Aug 12, 2022

BUY
$0.23 - $0.35 $21,703 - $33,027
94,365 Added 2.44%
3,967,720 $1.11 Million
Q1 2022

May 13, 2022

SELL
$0.28 - $0.68 $265,326 - $644,365
-947,596 Reduced 19.66%
3,873,355 $1.36 Million
Q4 2021

Feb 14, 2022

SELL
$0.6 - $1.04 $11,814 - $20,478
-19,691 Reduced 0.41%
4,820,951 $2.91 Million
Q3 2021

Nov 12, 2021

BUY
$0.99 - $1.38 $4,715 - $6,572
4,763 Added 0.1%
4,840,642 $4.99 Million
Q2 2021

Aug 13, 2021

BUY
$1.14 - $1.87 $5.51 Million - $9.04 Million
4,835,879 New
4,835,879 $6.09 Million

About TYME TECHNOLOGIES, INC.


  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.